ArticleLiver international : official journal of the International Association for the Study of the Liver2020
Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01607528 (Probiotic Modulation of Gut Microflora in Cirrhosis), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- [Assessment and management of malnutrition in patients with cirrhosis combined with hepatic encephalopathy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks.Current gastroenterology reports · 2024Review
- Resting energy expenditure in patients with liver cirrhosis: Indirect calorimetry vs. predictive equations.Asia Pacific journal of clinical nutrition · 2024Article
- Proton pump inhibitor use and risk of hepatic encephalopathy: A multicentre study.JHEP reports : innovation in hepatology · 2024Article
- Screening and assessment of malnutrition in patients with liver cirrhosis.Frontiers in nutrition · 2024Review
- Metagenome-based characterization of the gut bacteriome, mycobiome, and virome in patients with chronic hepatitis B-related liver fibrosis.Frontiers in microbiology · 2024Article
- Nutritional assessment in patients with liver cirrhosis.World journal of hepatology · 2022Review
- Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients.BMC microbiology · 2022Article
- Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis.Nutrients · 2022Article
- Malnutrition in Patients with Liver Cirrhosis.Nutrients · 2021Review
- Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study.Annals of surgical oncology · 2021Article
- Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study.Nutrients · 2020Article
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study.BMC geriatrics · 2020Article
- Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND &
aimsCompositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment-related factors affect microbiome composition most distinctively.
methods16S rDNA sequencing data of 88 cirrhotic outpatients were investigated. Factors influencing microbiome composition were analysed by univariate and multivariate redundancy analysis. The association of the identified factors with changes in diversity and taxonomic composition was studied in depth using analysis of composition of microbiome, LDA-effect size and least absolute shrinkage and selection operator regularized regression.
resultsDisease severity and aetiology, proton pump inhibitor (PPI) use, nutritional status, age and C-reactive protein are significant explanatory variables for faecal microbiome composition in liver cirrhosis. Despite some taxonomic overlaps especially between disease severity and PPI use, we could show that the effects of disease severity, aetiology, PPI use and age are independent factors influencing microbiome composition also in subgroup analyses.
conclusionOur cross sectional system biology study identifies disease severity, aetiology, PPI use and age as independent factors that influence microbiome composition in liver cirrhosis. In chronic diseases with high morbidity, such as liver cirrhosis, precise patient metadata documentation is of utmost importance in microbiome analysis. Further studies with a higher sample size are necessary to validate this finding. TRIAL REGISTRATION NUMBER: NCT01607528.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.